"*" indicates required fields
We created the first FDA-cleared device supports concurrent reading, allowing for faster reading with proven, superior, automatic nodule detection.
Our four FDA-cleared applications are designed to improve reading efficiency and accuracy across the hospital enterprise without requiring additional hardware.
Riverain’s deep learning AI technology is FDA cleared, field tested, and clinically proven to provide real results in radiology.
Riverain Technologies advanced AI imaging software is in use by leading healthcare organizations around the world.
Peer reviews, reference accounts, and independent studies confirm that ClearRead technology is positively impacting the field of radiology.
Managing your lung program can seem daunting, whether you’re getting going, growing, or managing workflow. We’ve curated resources for you.
Lung cancer is the #1 cancer killer in America and usually goes undetected until it’s too late. When found early, survival rates are dramatically higher. Riverain Technologies is dedicated to the early detection of lung cancer and creating better outcomes for patients everywhere.
Riverain ClearRead solutions significantly improve a clinician’s ability to accurately and efficiently detect disease in thoracic (lung) CT and XR images and more successfully address the challenges of early detection of lung disease. Powered by machine learning and advanced modeling, the patented, FDA-cleared ClearRead software tools are deployed in the clinic or the cloud and are powered by the most advanced AI methods available to the medical imaging market. While the benefit for patients can be life changing, the advantages for radiologists are equally substantial. Battling growing workloads and less time, ClearRead solutions allow clinicians to complete more reads faster – saving valuable time without sacrificing performance.
To save lives through the early detection, diagnosis, and management of lung disease.
To be recognized as a transformative leader in the thoracic sciences.
Dr. Jared Christensen is vice chair of strategy of the Duke University Department of Radiology and director of the Duke Lung Cancer Screening Program. He currently serves as chair of the American College of Radiology Lung-RADS Committee. Dr. Christensen’s professional interests in AI focus on finding solutions that decrease variability, increase efficiency, and improve patient outcomes.
Dr. Jonathan Chung, professor of radiology, chief, section of thoracic radiology, and chief quality officer at the University of Chicago Medicine, specializes in cardiopulmonary imaging. He analyzes and interprets chest radiographs and CT scans for thoracic diseases. He also has expertise in interstitial lung disease, occupational lung disease, nontuberculous mycobacterial pneumonia and diseases of the large and small airways. He has authored over 140 peer-reviewed articles that have been published in scientific journals, co-authored five book chapters and five books that focus on chest diagnostics.
Dr. Charles White has been on the Riverain advisory board since 2013, and is Professor of Radiology and Medicine at the University of Maryland Medical Center. Dr. White has a special interest in the diagnosis and staging of lung cancer and cardiac CT imaging. Dr. White was named one of Baltimore Magazine’s 2010 “Top Docs” for General Diagnostic Radiology.
Steve Worrell
Steve became CEO of Riverain Technologies in 2013 after joining Riverain as Vice President of Research in 2007. Prior to joining Riverain Technologies, he was a principal developer of iCAD’s SecondLook mammography computer aided detection (CAD) system. His primary focus was the development of iCAD’s microcalcification detection system. His earlier career included development of model based vision systems for military applications using synthetic aperture radar. Since joining Riverain Technologies his focus has been on developing, marketing, and commercializing Riverain’s X-ray and CT product lines.
Jason Knapp
Jason leads the research team in the development of advanced AI applications for medical imaging. He has been the principal developer of 7 FDA-approved products, which are used throughout the world, touching millions of lives each year.
Ofer Pinhasi
Ofer Pinhasi has been Chief Product Officer for Riverain Technologies since 2020. In this role, he leads the development and deployment of Riverain Technologies’ products in world markets, establishing governance processes, and leading the strategic planning effort to achieve business goals. Prior to joining Riverain, Ofer’s medical device experience spans artificial intelligence and CT/NM scanner design and production at GE and Philips.
Unlike many AI solutions, Riverain technology is verifed, validated, and FDA-cleared. Our technology has been substantiated by peer-reviewed articles, third party studies, and reference accounts. That’s why so many respected healthcare organizations have partnered with Riverain Technologies, allowing potential customers easy access to the power of the ClearRead Suite with the initial purchase of their imaging devices. You can contact these partners directly or work with a Riverain representative for more information.
Our technology is revolutionizing radiology. We’d love to work with you to help create better outcomes for patients everywhere.
